Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTA018 in chronic plaque psoriasis
NCT00384098Phase 2Completed
- Sponsor
- OPKO Health
- Start
- Sep 2006
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lunacalcipol in psoriasis (4 arms), sponsored by OPKO Health. Primary endpoint: Physician's Static Global Assessment Success at 12 weeks. Started Sep 2006; status: completed.
02
Drugs
lunacalcipol
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT00384098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00384098.